In light of the negative ENDEAVOUR outcome, and notwithstanding the similarities in revusiran-mediated TTR reductions between those who died on drug versus those who did not, an important question arises regarding the safety of TTR-lowering approaches in hATTR amyloidosis. Here, TTR is linked to amyloidosis.